Infliximab antibody | AbD20436_hIgG1
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human Anti-Infliximab Antibody (clone AbD20436_hIgG1) at a concentration of 2 μg/ml followed by QuantaBlu Fluorogenic Peroxidase Substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit.
A microtiter plate was coated over night with Human IgG1/kappa, Human IgG1/lambda, cetuximab or infliximab at a concentration of 5 µg/ml. After washing with PBST and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human Anti-Infliximab Antibody (clone AbD20436_hIgG1) titrated to the given concentrations in PBST, followed by QuantaBlu Fluorogenic Peroxidase Substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit.
A microtiter plate was coated over night with Human Anti-Infliximab (clone AbD20436, HCA234) at a concentration of 0.6 µg/ml. After washing and blocking with PBST+5% BSA, 10% Human serum was added spiked with increasing concentrations of infliximab. Detection was performed using HRP-conjugated Human Anti-Infliximab (clone AbD20436_hIgG1) at a concentration of 2 µg/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit.
A microtitre plate was coated over night with infliximab at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, 10% Human serum was added spiked with increasing concentrations of Human Anti-Infliximab (clone AbD20436_hIgG1). Detection was performed using HRP-conjugated infliximab at a concentration of 2 µg/ml in HISPEC Assay Diluent (BUF049) and QuantaBlu Fluorogenic Peroxidase Substrate. HRP-conjugation of infliximab used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit.
Human anti Infliximab
Anti-infliximab antibody is a recombinant, neutralizing, high affinity anti-idiotypic antibody in full IgG1 format, ideal for bioanalytical assays for infliximab and biosimilars. It can be used as the detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.
- Product Type
- Monoclonal Antibody
- Clone
- AbD20436_hIgG1
- Isotype
- IgG1
| Product Code | Applications | Datasheet | MSDS | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|---|
| HCA233 | E | 0.1 mg | ||||
| HCA233G | E | 1 mg |
Human Anti-Infliximab Antibody, clone AbD20436_hIgG1, is an affinity matured anti-idiotypic antibody that specifically recognizes free infliximab but not infliximab bound to its target, tumor necrosis factor alpha (TNFα). It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.
This antibody inhibits the binding of infliximab to TNFα and can be used as a detection antibody in a pharmacokinetic (PK) bridging ELISA to measure free drug. As it is a fully human antibody, it can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.
Infliximab (branded as Remicade) is a chimeric IgG1 kappa monoclonal antibody approved for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. This therapeutic antibody is directed against TNFα and acts by blocking the binding of TNFα to its receptors, resulting in a down-regulation of the inflammatory response associated with autoimmune diseases.
View a summary of all Anti-Infliximab Antibodies.
This antibody inhibits the binding of infliximab to TNFα and can be used as a detection antibody in a pharmacokinetic (PK) bridging ELISA to measure free drug. As it is a fully human antibody, it can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.
Infliximab (branded as Remicade) is a chimeric IgG1 kappa monoclonal antibody approved for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. This therapeutic antibody is directed against TNFα and acts by blocking the binding of TNFα to its receptors, resulting in a down-regulation of the inflammatory response associated with autoimmune diseases.
View a summary of all Anti-Infliximab Antibodies.
Product Details
- Product Form
- Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This product is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Infliximab
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD=0.12 nM by real time, label-free molecular interaction analysis on immobilized infliximab.
- Approx. Protein Concentrations
- Pack Size: 0.1 mgAntibody concentration 0.5 mg/mlPack Size: 1 mgAntibody concentration 1.0 mg/ml
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Shelf Life
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Remicade is a registered trademark of Janssen Biotech Inc. Inflectra is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS is a trademark of Merck Sharp & Dohme Corp.
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Infliximab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used in a direct ELISA or as a bridging antibody in ADA assay development.
Protocol: PK bridging ELISA to measure free drug
Protocol: ADA bridging ELISA
Copyright © 2018 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | 50 ml | E IY | ||
| Human anti Infliximab | HCA234 | 0.1 mg | E | ||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | 3 Conjugations For 400µg Antibody | CJ |
Product Specific References
References for Infliximab antibody
-
Lee, M.W. et al. (2016) Comparison of infliximab drug measurement across three commercially available ELISA kits.
Pathology. Aug 23. pii: S0031-3025(16)39762-8. [Epub ahead of print]
